Maint. Improv. of Outcomes rel. to Skin Clearance, Itch, Sleep & QoL with Baricitinib in Adults with Mod.-to-Sev. Atopic Dermatitis treated for up to 200 Weeks in a Randomized Trial


Por: Wollenberg, A, Costanzo, A, Vestergaard, C, Barbarot, S, Carrascosa, JM, Morawska, K, Vardar, B, Pandey, H, Sabatino, S, Silverberg, J and Schlöbe, A

Publicada: 1 abr 2025
Resumen:


Filiaciones:
Wollenberg, A:
 Ludwig Maximillian Univ, Univ Hosp, Munich, Germany

Costanzo, A:
 Univ Med Sch Dermatol, Via Alessandro Manzoni, Rozzano, Germany

Vestergaard, C:
 Aarhus Univ Hosp, Aarhus, Denmark

Barbarot, S:
 Univ Hosp Nantes, Nantes, France

:
 Hosp Univ Germans Trias I Pujol, Barcelona, Spain

Morawska, K:
 Eli Lilly & Co, Indianapolis, IN USA

Vardar, B:
 Eli Lilly & Co, Indianapolis, IN USA

Pandey, H:
 Eli Lilly & Co, Indianapolis, IN USA

Sabatino, S:
 Eli Lilly & Co, Indianapolis, IN USA

Silverberg, J:
 George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

Schlöbe, A:
 Lilly Deutschland, Bad Homburg, Germany
ISSN: 16100379





JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
Editorial
Blackwell Publishing Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Meeting Abstract
Volumen: 23 Número:
Páginas:
WOS Id: 001515598600310

MÉTRICAS